Argenx Advances Efgartigimod Into China With Zai Lab Pact
Selects Option Of $75m In Stock For Upfront
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
You may also be interested in...
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
The company's first-in-class FcRn antagonist, which has an FDA action date in December, is now being reviewed by the EMA and although the regulator rejected a request for an accelerated assessment of efgartigimod for generalized myasthenia gravis, commercial teams are being built up in Europe.
The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.